Harm reduction

Not to be confused with Harm principle or Conflict resolution.

Needle exchange programs provide people who inject substances with new needles and injection equipment to reduce the harm (e.g., HIV infection) from needle drug use.

Drug paraphernalia available from a harm reduction NGO at a mobile supervised injection site in Berlin, Germany.

Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal.^[1] Harm reduction is used to decrease negative consequences of recreational drug use and sexual activity without requiring abstinence, recognizing that those unable or unwilling to stop can still make positive change to protect themselves and others.^[2][3]

Harm reduction is most commonly applied to approaches that reduce adverse consequences from drug use, and harm reduction programs now operate across a range of services and in different regions of the world. As of 2020, some 86 countries had one or more programs using a harm reduction approach to substance use, primarily aimed at reducing blood-borne infections resulting from use of contaminated injecting equipment.^[4]

Needle-exchange programmes reduce the likelihood of people who use heroin and other substances sharing the syringes and using them more than once. Syringe-sharing often leads to the spread of infections such as HIV or hepatitis C, which can easily spread from person to person through the reuse of syringes contaminated with infected blood. Needle and syringe programmes (NSP) and Opioid Agonist Therapy (OAT) outlets in some settings offer basic primary health care. Supervised injection sites are legally sanctioned, medically supervised facilities designed to provide a safe, hygienic, and stress-free environment for people who use substances. The facilities provide sterile injection equipment, information about substances and basic health care, treatment referrals, and access to medical staff.

Opioid agonist therapy (OAT) is the medical procedure of using a harm-reducing opioid that produces significantly less euphoria, such as methadone or buprenorphine to reduce opioid cravings in people who use illegal opioids, such as heroin; buprenorphine and methadone are taken under medical supervision. Another approach is heroin assisted treatment, in which medical prescriptions for pharmaceutical heroin (diacetylmorphine) are provided to people who are dependent on heroin.

Media campaigns inform drivers of the dangers of driving drunk. Most people who recreationally consume alcohol are now aware of these dangers and safe ride techniques like 'designated drivers' and free taxicab programmes are reducing the number of drunk-driving crashes. Many schools now provide safer sex education to teen and pre-teen students, who may engage in sexual activity. Since some adolescents are going to have sex, a harm-reductionist approach supports a sexual education which emphasizes the use of protective devices like condoms and dental dams to protect against unwanted pregnancy and the transmission of STIs. Since 1999, some countries have legalized or decriminalized prostitution, such as Germany (2002) and New Zealand (2003).

Many street-level harm-reduction strategies have succeeded in reducing HIV transmission in people who inject substances and sex-workers.^[5] HIV education, HIV testing, condom use, and safer-sex negotiation greatly decreases the risk of acquiring and transmitting the HIV virus.^[5]

Substance use

See also: Responsible drug use and Drug liberalization

In the case of recreational substance use, harm reduction is put forward as a useful perspective alongside the more conventional approaches of demand and supply reduction.^[6] Many advocates argue that prohibitionist laws criminalise people for suffering from a disease and cause harm for example, by obliging people who use substances to obtain substances of unknown purity from unreliable criminal sources at high prices, thereby increasing the risk of overdose and death.^[7] The web forum Bluelight allows users to share information and first-hand experience reports about various psychoactive substances and harm reduction practices.^[8] The website Erowid collects and publishes information and first-hand experience reports about all kinds of substances to educate people who use or may use substances.^[9]

While the vast majority of harm reduction initiatives are educational campaigns or facilities that aim to reduce substance-related harm, a unique social enterprise was launched in Denmark in September 2013 to reduce the financial burden of illicit substance use for people with a drug dependence. Michael Lodberg Olsen, who was previously involved with the establishment of a substance consumption facility in Denmark, announced the founding of the Illegal magazine that will be sold by people who use substances in Copenhagen and the district of Vesterbro, who will be able to direct the profits from sales towards drug procurement. Olsen explained: "No one has solved the problem of drug addiction, so is it not better that people find the money to buy their drugs this way than through crime and prostitution?"^[10]

Substances

Depressants

Alcohol

See also: Fomepizole and Denatured alcohol § Toxicity

Traditionally, homeless shelters ban alcohol. In 1997, as the result of an inquest into the deaths of two people experiencing homelessness who recreationally used alcohol two years earlier, Toronto's Seaton House became the first homeless shelter in Canada to operate a "wet shelter" on a "managed alcohol" principle in which clients are served a glass of wine once an hour unless staff determine that they are too inebriated to continue. Previously, people experiencing homelessness who consumed excessive amounts of alcohol opted to stay on the streets often seeking alcohol from unsafe sources such as mouthwash, rubbing alcohol or industrial products which, in turn, resulted in frequent use of emergency medical facilities. The programme has been duplicated in other Canadian cities, and a study of Ottawa's "wet shelter" found that emergency room visit and police encounters by clients were cut by half.^[11] The study, published in the Canadian Medical Association Journal in 2006, found that serving people experiencing long-term homelessness and who consume excessive amounts of alcohol controlled doses of alcohol also reduced their overall alcohol consumption. Researchers found that programme participants cut their alcohol use from an average of 46 drinks a day when they entered the programme to an average of 8 drinks and that their visits to emergency rooms dropped from 13.5 to an average of 8 per month, while encounters with the police fall from 18.1 to an average of 8.8.^[12][13]

Downtown Emergency Service Center (DESC),^[14] in Seattle, Washington, operates several Housing First programmes which utilize the harm reduction model. University of Washington researchers, partnering with DESC, found that providing housing and support services for homeless alcoholics costs taxpayers less than leaving them on the street, where taxpayer money goes towards police and emergency health care. Results of the study funded by the Substance Abuse Policy Research Program (SAPRP) of the Robert Wood Johnson Foundation^[15] appeared in the Journal of the American Medical Association in April 2009.^[16] This first controlled assessment in the U.S. of the effectiveness of Housing First, specifically targeting chronically homeless alcoholics, showed that the programme saved taxpayers more than $4 million over the first year of operation. During the first six months, the study reported an average cost-savings of 53 percent (even after considering the cost of administering the housing's 95 residents)—nearly $2,500 per month per person in health and social services, compared to the per month costs of a wait-list control group of 39 homeless people. Further, despite the fact residents are not required to be abstinent or in treatment for alcohol use, stable housing also results in reduced drinking among people experiencing homelessness who recreationally use alcohol.

Alcohol-related programmes

A high amount of media coverage exists informing people of the dangers of driving drunk. Most people who recreationally consume alcohol are now aware of these dangers and safe ride techniques like 'designated drivers' and free taxicab programmes are reducing the number of drunk-driving crashes. Many cities have free-ride-home programmes during holidays involving high amounts of alcohol use, and some bars and clubs will provide a visibly drunk patron with a free cab ride.

In New South Wales groups of licensees have formed local liquor accords and collectively developed, implemented and promoted a range of harm minimisation programmes including the aforementioned 'designated driver' and 'late night patron transport' schemes. Many of the transport schemes are free of charge to patrons, to encourage them to avoid drink-driving and at the same time reduce the impact of noisy patrons loitering around late night venues.

Moderation Management is a programme which helps drinkers to cut back on their consumption of alcohol by encouraging safe drinking behaviour.

Harm reduction in alcohol dependency could be instituted by use of naltrexone.^[17]

Opioids

Heroin maintenance programmes (HAT)

Main article: Heroin assisted treatment

Providing medical prescriptions for pharmaceutical heroin (diacetylmorphine) to heroin-dependent people has been employed in some countries to address problems associated with the illicit use of the drug, as potential benefits exist for the individual and broader society. Evidence has indicated that this form of treatment can greatly improve the health and social circumstances of participants, while also reducing costs incurred by criminalisation, incarceration and health interventions.^[18][19]

In Switzerland, heroin assisted treatment is an established programme of the national health system. Several dozen centres exist throughout the country and heroin-dependent people can administer heroin in a controlled environment at these locations. The Swiss heroin maintenance programme is generally regarded as a successful and valuable component of the country's overall approach to minimising the harms caused by illicit drug use.^[20] In a 2008 national referendum, a majority of 68 per cent voted in favour of continuing the Swiss programme.^[21]

The Netherlands has studied medically supervised heroin maintenance.^[22] A German study of long-term heroin addicts demonstrated that diamorphine was significantly more effective than methadone in keeping patients in treatment and in improving their health and social situation.^[23] Many participants were able to find employment, some even started a family after years of homelessness and delinquency.^[24][25] Since then, treatment had continued in the cities that participated in the pilot study, until heroin maintenance was permanently included into the national health system in May 2009.^[26] As of 2021, the country offers heroin-assisted treatment by prescribing medical-grade heroin is typically prescribed in combination with methadone and psychosocial counseling.^[27]

A heroin maintenance programme has existed in the United Kingdom (UK) since the 1920s, as drug addiction was seen as an individual health problem. Addiction to opiates was rare in the 1920s and was mostly limited to either middle-class people who had easy access due to their profession, or people who had become addicted as a side effect of medical treatment. In the 1950s and 1960s a small number of doctors contributed to an alarming increase in the number of people who are experiencing addiction in the U.K. through excessive prescribing—the U.K. switched to more restrictive drug legislation as a result.^[28] However, the British government is again moving towards a consideration of heroin prescription as a legitimate component of the National Health Service (NHS). Evidence has shown that methadone maintenance is not appropriate for all people who are dependent on opioids and that heroin is a viable maintenance drug that has shown equal or better rates of success.^[29]

A committee appointed by the Norwegian government completed an evaluation of research reports on heroin maintenance treatment that were available internationally. In 2011 the committee concluded that the presence of numerous uncertainties and knowledge gaps regarding the effects of heroin treatment meant that it could not recommend the introduction of heroin maintenance treatment in Norway.^[30]

Critics of heroin maintenance programmes object to the high costs of providing heroin to people who use it. The British heroin study cost the British government £15,000 per participant per year, roughly equivalent to average person who uses heroin's expense of £15,600 per year.^[31] Drug Free Australia^[32] contrast these ongoing maintenance costs with Sweden's investment in, and commitment to, a drug-free society where a policy of compulsory rehabilitation of people who are experiencing drug addiction is integral, which has yielded to one of the lowest reported illicit drug use levels in the developed world,^[33] a model in which successfully rehabilitated people who use substances present no further maintenance costs to their community, as well as reduced ongoing health care costs.^[32]

King's Health Partners notes that the cost of providing free heroin for a year is about one-third of the cost of placing the person in prison for a year.^{[dead link‍][34][35]}

Naloxone distribution

Naloxone is a drug used to counter an overdose from the effect of opioids; for example, a heroin or morphine overdose. Naloxone displaces the opioid molecules from the brain's receptors and reverses the respiratory depression caused by an overdose within two to eight minutes.^[36] The World Health Organization (WHO) includes naloxone on their "List of Essential Medicines", and recommends its availability and utilization for the reversal of opioid overdoses.^[37][38]

Formal programs in which the opioid inverse agonist drug naloxone is distributed have been trialled and implemented. Established programs distribute naloxone, as per WHO's minimum standards, to people who use substances and their peers, family members, police, prisons, and others. These treatment programs and harm reduction centres operate in Afghanistan, Australia, Canada, China, Germany, Georgia, Kazakhstan, Norway, Russia, Spain, Tajikistan, the United Kingdom (UK), the United States (US), Vietnam,^[39] India, Thailand, Kyrgyzstan,^[40] Denmark and Estonia.^[41] Many reviews of the literature support the effectiveness of naloxone based interventions in reducing overdose deaths where it is available at the time of the overdose event.^[42][43] This effectiveness has been explained in a Realist Evaluation which explained the effectiveness through bystander effect, social identity theory, and skills training such that universal access to training supports social identity and in-group norms (of people who use drugs), which supports the conditions for the success of a peer-to-peer distribution model of naloxone-based interventions. Stigma and stigmatising attitudes reduced the effectiveness of naloxone based interventions.^[44]

Medication assisted treatment (MAT): Opioid agonist therapy (OAT) and Opioid substitution therapy (OST)

Medication assisted treatment (MAT) is the prescription of legal, prescribed opioids or other drugs, often long-acting, to diminish the use of illegal opioids. Many types of MAT exist, including opioid agonist therapy (OAT) where a safer opioid agonist is employed or opioid substitution therapy (OST) which employs partial opioid agonists. However, MAT, OAT, OST are often used synonymously.^[45]

Opioid agonist therapy (OAT) involves the use of a full opioid agonist treatment like methadone and is generally taken daily at a clinic.^[46][47] Opioid substitution therapy (OST) involves the use of the partial agonist buprenorphine or a combination of buprenorphine/naloxone (brand name Suboxone). Oral/sublingual formulations of buprenorphine incorporate the opioid antagonist naloxone to prevent people from crushing the tablets and injecting them.^[46] Unlike methadone treatment, buprenorphine therapy can be prescribed month-to-month and obtained at a traditional pharmacy rather than a clinic.^[48]

The driving principle behind OAT/OST is the program's capacity to facilitate a resumption of stability in the person's life, while they experience reduced symptoms of withdrawal symptoms and less intense drug cravings; however, a strong euphoric effect is not experienced as a result of the treatment drug.^[46]

In some countries, such as Switzerland, Austria, and Slovenia, patients are treated with slow-release morphine when methadone is deemed inappropriate due to the individual's circumstances. In Germany, dihydrocodeine has been used off-label in OAT for many years, however it is no longer frequently prescribed for this purpose. Extended-release dihydrocodeine is again in current use in Austria for this reason.^{[citation needed]} Research into the usefulness of piritramide, extended-release hydromorphone (including polymer implants lasting up to 90 days), dihydroetorphine and other substances for OAT is at various stages in a number of countries.^[46] In 2020 in Vancouver, Canada, health authorities began vending machine dispensing of hydromorphone tablets as a response to elevated rates of fatal overdose from street drugs contaminated with fentanyl and fentanyl analogues.^[49]

In some countries (not the US, UK, Canada, or Australia),^[46] regulations enforce a limited time period for people on OAT/OST programs that conclude when a stable economic and psychosocial situation is achieved. (Patients with HIV/AIDS or hepatitis C are usually excluded from this requirement.) In practice, 40–65% of patients maintain complete abstinence from opioids while receiving opioid agonist therapy, and 70–95% are able to reduce their use significantly, while experiencing a concurrent elimination or reduction in medical (improper diluents, non-sterile injecting equipment), psychosocial (mental health, relationships), and legal (arrest and imprisonment) issues that can arise from the use of illicit opioids.^[46]

OAT/OST outlets in some settings also offer basic primary health care. These are known as 'targeted primary health care outlet'—as these outlets primarily target people who inject drugs and/or 'low-threshold health care outlet'—as these reduce common barriers clients often face when they try to access health care from the conventional health care outlets.^[50][51] For accessing sterile injecting equipment clients frequently visit NSP outlets, and for receiving pharmacotherapy (e.g. methadone, buprenorphine) they visit OST clinics; these frequent visits are used opportunistically to offer much needed health care.^[52][53] These targeted outlets have the potential to mitigate clients' perceived barriers to access to healthcare delivered in traditional settings. The provision of accessible, acceptable and opportunistic services which are responsive to the needs of this population is valuable, facilitating a reduced reliance on inappropriate and cost-ineffective emergency department care.^[54][55]

Cannabis

Further information: Cannabis (drug), Legal issues of cannabis, and Health issues and the effects of cannabis

Specific harms associated with cannabis include increased crash-rate while driving under intoxication, dependence, psychosis, detrimental psychosocial outcomes for adolescents who use substances, and respiratory disease.^[56] Some safer cannabis usage campaigns including the UKCIA (United Kingdom Cannabis Internet Activists) encourage methods of consumption shown to cause less physical damage to a person's body, including oral (eating) consumption, vaporization, the usage of bongs which cool and to some extent filters the smoke, and smoking the cannabis without mixing it with tobacco.

The fact that cannabis possession carries prison sentences in most developed countries is also pointed out as a problem by European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), as the consequences of a conviction for otherwise law-abiding people who use substances arguably is more harmful than any harm from the substance itself. For example, by adversely affecting employment opportunities, impacting civil rights,^[57] and straining personal relationships.^[58] Some people like Ethan Nadelmann of the Drug Policy Alliance have suggested that organized marijuana legalization would encourage safe use and reveal the factual adverse effects from exposure to this herb's individual chemicals.^[59]

The way the laws concerning cannabis are enforced is also very selective, even discriminatory. Statistics show that the socially disadvantaged, immigrants and ethnic minorities have significantly higher arrest rates.^[58] Drug decriminalisation, such as allowing the possession of small amounts of cannabis and possibly its cultivation for personal use, would alleviate these harms.^[58] Where decriminalisation has been implemented, such as in several states in Australia and United States, as well as in Portugal and the Netherlands no, or only very small adverse effects have been shown on population cannabis usage rate.^[58] The lack of evidence of increased use indicates that such a policy shift does not have adverse effects on cannabis-related harm while, at the same time, decreasing enforcement costs.^[58]

In the last few years certain strains of the cannabis plant with higher concentrations of THC and drug tourism have challenged the former policy in the Netherlands and led to a more restrictive approach; for example, a ban on selling cannabis to tourists in coffeeshops suggested to start late 2011.^[60] Sale and possession of cannabis is still illegal in Portugal^[61] and possession of cannabis is a federal crime in the United States.

Psychedelics

The Zendo Project conducted by the Multidisciplinary Association for Psychedelic Studies uses principles from psychedelic therapy to provide safe places and emotional support for people having difficult experiences on psychedelic drugs at select festivals such as Burning Man, Boom Festival, and Lightning in a Bottle without medical or law enforcement intervention.^[62]

Stimulants

The United Nations Office on Drugs and Crime states, "While medical models of treatment for individuals with alcohol or opioid use disorders are well accepted and implemented worldwide, in most countries there is no parallel, long-term medical model of treatment for individuals with stimulant use disorders."^[63] The neglect of stimulant-users has been widely considered to be related to the popularity of stimulants among systemically-oppressed groups, such as methamphetamine use among gay men and transgender people, and crack cocaine use among Black people.^[64][65] The crack epidemic in the United States demonstrates a discrepancy between sentencing lengths of crack cocaine and heroin users, with crack users imprisoned for longer periods of time than heroin users. In 2012, 88% of imprisonments from crack cocaine were of African American people.^[66]

Stimulant users have increasingly been at risk for opioid overdose since 2006, due to the nonconsensual presence of fentanyl in their substances.^[67]

Tobacco

Main article: Tobacco harm reduction

Tobacco harm reduction describes actions taken to lower the health risks associated with using tobacco, especially combustible forms, without abstaining completely from tobacco and nicotine. Some of these measures include switching to safer (lower tar) cigarettes, switching to snus or dipping tobacco, or using a non-tobacco nicotine delivery systems. In recent years, the growing use of electronic cigarettes (or vaping) for smoking cessation, whose long-term safety remains uncertain, has sparked an ongoing controversy among medical and public health between those who seek to restrict and discourage all use until more is known and those who see them as a useful approach for harm reduction, whose risks are most unlikely to equal those of smoking tobacco.^[68] "Their usefulness in tobacco harm reduction as a substitute for tobacco products is unclear",^[69] but in an effort to decrease tobacco related death and disease, they have a potential to be part of the strategy.^[70]

Routes of administration

Needle exchange programmes (NEP)

A bin allowing for safe disposal of needles in a public toilet in Caernarfon, Wales

Main article: Needle-exchange programme

The use of some illicit drugs can involve hypodermic needles. In some areas (notably in many parts of the US), these are available solely by prescription. Where availability is limited, people who use heroin and other substances frequently share the syringes and use them more than once or participate in unsafe practices such as blood flashing. As a result, infections such as HIV or hepatitis C can spread from person to person through the reuse of syringes contaminated with infected blood.^[71] The principles of harm reduction propose that syringes should be easily available or at least available through a needle and syringe programmes (NSP). Where syringes are provided in sufficient quantities, rates of HIV are much lower than in places where supply is restricted. In many countries people who use substances are supplied equipment free of charge, others require payment or an exchange of dirty needles for clean ones, hence the name.

A 2010 review found insufficient evidence that NSP prevents transmission of the hepatitis C virus, tentative evidence that it prevents transmission of HIV and sufficient evidence that it reduces self-reported injecting risk behaviour.^[72] It has been shown in the many evaluations of needle-exchange programmes that in areas where clean syringes are more available, illegal drug use is no higher than in other areas. Needle exchange programmes have reduced HIV incidence by 33% in New Haven and 70% in New York City.^[73]

The Melbourne, Australia inner-city suburbs of Richmond and Abbotsford are locations in which the use and dealing of heroin has been concentrated for a protracted time period. Research organisation the Burnet Institute completed the 2013 'North Richmond Public Injecting Impact Study' in collaboration with the Yarra Drug and Health Forum, City of Yarra and North Richmond Community Health Centre and recommended 24-hour access to sterile injecting equipment due to the ongoing "widespread, frequent and highly visible" nature of illicit drug use in the areas. During the period between 2010 and 2012 a four-fold increase in the levels of inappropriately discarded injecting equipment was documented for the two suburbs. In the local government area the City of Yarra, of which Richmond and Abbotsford are parts of, 1550 syringes were collected each month from public syringe disposal bins in 2012. Furthermore, ambulance callouts for heroin overdoses were 1.5 times higher than for other Melbourne areas in the period between 2011 and 2012 (a total of 336 overdoses), and drug-related arrests in North Richmond were also three times higher than the state average. The Burnet Institute's researchers interviewed health workers, residents and local traders, in addition to observing the drug scene in the most frequented North Richmond public injecting locations.^[74]

On 28 May 2013, the Burnet Institute stated in the media that it recommends 24-hour access to sterile injecting equipment in the Melbourne suburb of Footscray after the area's drug culture continues to grow after more than ten years of intense law enforcement efforts. The institute's research concluded that public injecting behaviour is frequent in the area and inappropriately discarding injecting paraphernalia has been found in carparks, parks, footpaths and drives. Furthermore, people who inject drugs have broken open syringe disposal bins to reuse discarded injecting equipment.^[75]

The British public body, the National Institute for Health and Care Excellence (NICE), introduced a new recommendation in early April 2014 due to an increase in the presentation of the number of young people who inject steroids at UK needle exchanges. NICE previously published needle exchange guidelines in 2009, in which needle and syringe services are not advised for people under the age of 18 years, but the organisation's director Professor Mike Kelly explained that a "completely different group" of people were presenting at programs. In the updated guidance, NICE recommended the provision of specialist services for "rapidly increasing numbers of steroid users", and that needles should be provided to people under the age of 18—a first for NICE—following reports of 15-year-old steroid injectors seeking to develop their muscles.^[76]

Supervised injection sites (SIS)

A clandestine kit containing materials to inject drugs

Injection kit obtained from a needle-exchange programme

Main article: Supervised injection site

Supervised injection sites (SIS), or Drug consumption rooms (DCR), are legally sanctioned, medically supervised facilities designed to address public nuisance associated with drug use and provide a hygienic and stress-free environment for drug consumers.

The facilities provide sterile injection equipment, information about drugs and basic health care, treatment referrals, and access to medical staff. Some offer counseling, hygienic and other services of use to itinerant and impoverished individuals. Most programmes prohibit the sale or purchase of illegal drugs. Many require identification cards. Some restrict access to local residents and apply other admission criteria, such as they have to be people who inject substances, but generally in Europe they do not exclude people with substance use disorders who consume their substances through other means.

The Netherlands had the first staffed injection room, although they did not operate under explicit legal support until 1996. Instead, the first center where it was legal to inject drugs was in Berne, Switzerland, opened 1986. In 1994, Germany opened its first site. Although, as in the Netherlands they operated in a "gray area", supported by the local authorities and with consent from the police until the Bundestag provided a legal exemption in 2000.^[77]

In Europe, Luxembourg, Spain and Norway have opened facilities after year 2000.^[78] Sydney's Medically Supervised Injecting Center (MSIC) was established in May 2001 as a trial and Vancouver's Insite opened in September 2003.^[79][80][81] In 2010, after a nine-year trial, the Sydney site was confirmed as a permanent public health facility.^[82][83] As of late 2009 there were a total of 92 professionally supervised injection facilities in 61 cities.^[78] In North American, as of 2023 there are supervised injection sites operating in a number of Canadian cities,^[84] and two in United States. The sites in United States opened in 2021.^[85]

The European Monitoring Centre for Drugs and Drug Addiction's latest systematic review from April 2010 did not find any evidence to support concerns that DCR might "encourage drug use, delay treatment entry or aggravate problems of local drug markets."^[78] Jürgen Rehm and Benedikt Fischer explained that while evidence show that DCR are successful, that "interpretation is limited by the weak designs applied in many evaluations, often represented by the lack of adequate control groups." Concluding that this "leaves the door open for alternative interpretations of data produced and subsequent ideological debate."^[86]

The EMCDDA review noted that research into the effects of the facilities "faces methodological challenges in taking account of the effects of broader local policy or ecological changes", still they concluded "that the facilities reach their target population and provide immediate improvements through better hygiene and safety conditions for injectors." Further that "the availability of safer injecting facilities does not increase levels of drug use or risky patterns of consumption, nor does it result in higher rates of local drug acquisition crime." While its usage is "associated with self-reported reductions in injecting risk behaviour such as syringe sharing, and in public drug use" and "with increased uptake of detoxification and treatment services."^[78] However, "a lack of studies, as well as methodological problems such as isolating the effect from other interventions or low coverage of the risk population, evidence regarding DCRs—while encouraging—is insufficient for drawing conclusions with regard to their effectiveness in reducing HIV or hepatitis C virus (HCV) incidence." Concluding with that "there is suggestive evidence from modelling studies that they may contribute to reducing drug-related deaths at a city level where coverage is adequate, the review-level evidence of this effect is still insufficient."^[78]

Critics of this intervention, such as drug prevention advocacy organisations, Drug Free Australia and Real Women of Canada^[83][87][88] point to the most rigorous evaluations,^[89] those of Sydney and Vancouver. Two of the centers, in Sydney, Australia and Vancouver, British Columbia, Canada cost $2.7 million^[90] and $3 million per annum to operate respectively,^[91] yet Canadian mathematical modeling, where there was caution about validity, indicated just one life saved from fatal overdose per annum for Vancouver,^[92][93] while the Drug Free Australia analysis demonstrates the Sydney facility statistically takes more than a year to save one life.^[94] The Expert Advisory Committee of the Canadian Government studied claims by journal studies for reduced HIV transmission by Insite but "were not convinced that these assumptions were entirely valid."^[92] The Sydney facility showed no improvement in public injecting and discarded needles beyond improvements caused by a coinciding heroin drought,^[95] while the Vancouver facility had an observable impact.^[92] Drug dealing and loitering around the facilities were evident in the Sydney evaluation,^[96] but not evident for the Vancouver facility.^[92]

Safer supply

Safer supply programs prescribe medications (including stimulants, opioids, and benzodiazepines) to people at high risk of overdose. This is meant to provide a safer alternative to an illegal drug supply that contains high levels of fentanyl and other dangerous chemicals.^[97] The structure of such programs is more flexible than opioid agonist therapy.^[97] The drugs dispensed by these programs can result in intoxication, unlike methadone or buprenorphine.^[98] Safer supply projects exist in a number of Canadian cities.^[84] Critics of these programs point to the risk of drug diversion and argue that patients should be encouraged to enter drug rehabilitation programs instead of being given drugs.^[98]

Sex

Safer sex programmes

Many schools now provide safer sex education to teen and pre-teen students, who may engage in sexual activity. Since some adolescents are going to have sex, a harm-reductionist approach supports a sexual education which emphasizes the use of protective devices like condoms and dental dams to protect against unwanted pregnancy and the transmission of STIs. This runs contrary to abstinence-only sex education, which teaches that educating children about sex can encourage them to engage in it.

These programmes have been found to decrease risky sexual behaviour and prevent sexually transmitted infections.^[99] They also reduce rates of unwanted pregnancies.^[100] Abstinence-only programmes do not appear to affect HIV risks in developed countries with no evidence available for other areas.^[101]

Legalized prostitution

Main article: Legality of prostitution

Since 1999, some countries have legalized prostitution, such as Germany (2002) and New Zealand (2003). However, in most countries the practice is prohibited. Gathering accurate statistics on prostitution and human trafficking is extremely difficult. This has resulted in proponents of legalization claiming that it reduces organized crime rates while opponents claim exactly the converse. The Dutch prostitution policy, which is one of the most liberal in the world, has gone back and forth on the issue several times. In the period leading up to 2015 up to a third of officially sanctioned work places had been closed down again after reports of human trafficking. Prostitutes themselves are generally opposed to what they see as "theft of their livelihood".^[102]

Legal prostitution means prostitutes can contact police in instances of abuse or violence without fear of arrest or prosecution because of what they are doing being illegal. A legal and regulated system can also provide licensed brothels as opposed to prostitutes working on the streets, in which the owners or staff of the premises can call the police in instances of violence against sex workers without fear of workers or the business facing criminal charges or being shut down. Legal and regulated prostitution can require prostitutes to undergo regular health checks for sexually transmitted infections (STIs) by law. Sex workers in Nevada for instance have to get monthly tests for syphilis and HIV and weekly tests for gonorrhea and chlamydia.^[103]

Sex-work and HIV

Despite the depth of knowledge of HIV/AIDS, rapid transmission has occurred globally in sex workers.^[73] The relationship between these two variables greatly increases the risk of transmission among these populations, and also to anyone associated with them, such as their sexual partners, their children, and eventually the population at large.^[73]

Many street-level harm-reduction strategies have succeeded in reducing HIV transmission in injecting drug users and sex-workers.^[5] HIV education, HIV testing, condom use, and safer-sex negotiation greatly decreases the risk to the disease.^[5][104] Peer education as a harm reduction strategy has especially reduced the risk of HIV infection, such as in Chad, where this method was the most cost-effective per infection prevented.^[5]

Decriminalisation as a harm-reduction strategy gives the ability to treat substance use disorder solely as a public health issue rather than a criminal activity. This enables other harm-reduction strategies to be employed, which results in a lower incidence of HIV infection.^[105]

One of the first harm reduction models was called the "Mersey Harm Reduction Model" in 1980s Liverpool, and the success of utilizing outreach workers, distribution of education, and providing clean equipment to drug users was shown in the fact that an HIV epidemic did not happen in Mersey.^[106]

The AIDS epidemic, which began in the 80s and peaked in 1995, further complicated the politicization of drug users and drug use in the US. The implementation of harm reduction faced much resistance within the US due to the demonization of particular drugs associated with stigmatized groups, such as sex workers and drug-injecting users.^[107]

Decriminalisation

Decriminalisation as a harm-reduction strategy gives the ability to treat substance use disorder solely as a public health issue rather than a criminal activity. This enables other harm-reduction strategies to be employed, which results in a lower incidence of HIV infection.^[5]

Criticism

Critics, such as Drug Free America Foundation and other members of network International Task Force on Strategic Drug Policy, state that a risk posed by harm reduction is by creating the perception that certain behaviours can be partaken of safely, such as illicit drug use, that it may lead to an increase in that behaviour by people who would otherwise be deterred. The signatories of the drug prohibitionist network International Task Force on Strategic Drug Policy stated that they oppose drug use harm reduction "...strategies as endpoints that promote the false notion that there are safe or responsible ways to use drugs. That is, strategies in which the primary goal is to enable drug users to maintain addictive, destructive, and compulsive behavior by misleading users about some drug risks while ignoring others."^[108]

In 2008, the World Federation Against Drugs stated that while "...some organizations and local governments actively advocate the legalization of drugs and promote policies such as "harm reduction" that accept drug use and do not help people who use substances to become free from substance use. This undermines the international efforts to limit the supply of and demand for drugs." The Federation states that harm reduction efforts often end up being "drug legalization or other inappropriate relaxation efforts, a policy approach that violates the UN Conventions."^[109]

Critics furthermore reject harm reduction measures for allegedly trying to establish certain forms of drug use as acceptable in society. The Drug Prevention Network of Canada states that harm reduction has "...come to represent a philosophy in which illicit substance use is seen as largely unpreventable, and increasingly, as a feasible and acceptable lifestyle as long as use is not 'problematic'", an approach which can increase "acceptance of drug use into the mainstream of society". They say harm reduction "...sends the wrong message to ... children and youth" about drug use.^[110] In 2008, the Declaration of World Forum Against Drugs criticized harm reduction policies that "...accept drug use and do not help drug users to become free from drug abuse", which the group say undermines "...efforts to limit the supply of and demand for drugs." They state that harm reduction should not lead to less efforts to reduce drug demand.^[111]

Pope Benedict XVI criticised harm reduction policies with regards to HIV/AIDS, saying that it was "a tragedy that cannot be overcome by money alone, that cannot be overcome through the distribution of condoms, which even aggravates the problems".^[112] This position was in turn widely criticised for misrepresenting and oversimplifying the role of condoms in preventing infections.^[113][114]

See also

• Aubri Esters
• Bluelight (web forum)
• Demand reduction
• Erowid
• Harm reduction in the United States
• Low-threshold treatment programs
• Mitigation
• Supervised injection site
• Supply reduction

References

1. Marshall, Zack; B.R. Smith, Christopher (2016). Critical Approaches to Harm Reduction: Conflict, Institutionalization, (de-)politicization, and Direct Action. New York: Nova Publishers. ISBN 978-1-63484-902-9. OCLC 952337014. Archived from the original on 25 February 2024. Retrieved 17 April 2023.
2. What is Harm Reduction?. New York: Open Society Foundations. June 2021. Archived from the original on 27 July 2023.
3. Harm Reduction International. "What Is Harm Reduction?". Archived from the original on 10 January 2022. Retrieved 10 January 2022.
4. Global State of Harm Reduction 2020 (PDF). London: Harm Reduction International. 2021. pp. 18–23. Archived (PDF) from the original on 14 March 2023.
5. Rekart ML (December 2005). "Sex-work harm reduction" (PDF). Lancet. 366 (9503): 2123–2134. doi:10.1016/S0140-6736(05)67732-X. PMID 16360791. S2CID 11448309. Archived from the original (PDF) on 6 January 2017.
6. Marlatt, G. Alan (2002). "Highlights of Harm Reduction". Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors. Guilford Press. p. 3. ISBN 978-1-57230-825-1.
7. Inciardi, James A.; Harrison, Lana D. (2000). Harm reduction: national and international perspectives. Thousand Oaks, California: Sage. pp. vii–viii.
8. Barratt, Monica J. (2 January 2017). "Bluelight.org: a harm-reduction community that supports public health research". Journal of Substance Use. 22 (1): 1–2. doi:10.1080/14659891.2016.1208779. ISSN 1465-9891.
9. Witt, Emily (15 November 2015). "A Field Guide to Psychedelics". The New Yorker. ISSN 0028-792X. Archived from the original on 3 May 2020. Retrieved 14 March 2024.
10. Daniel Boffey (8 September 2013). "Dane launches street magazine to help drug users fund their habit". The Guardian. Archived from the original on 11 June 2019. Retrieved 6 November 2013.
11. McKeen, Scott (7 March 2007). "'Wet' shelter needs political will: Toronto project could serve as model for Edmonton". Edmonton Journal.
12. Podymow T, Turnbull J, Coyle D, Yetisir E, Wells G (2006). "Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol". CMAJ. 174 (1): 45–49. doi:10.1503/cmaj.1041350. PMC 1319345. PMID 16389236.
13. Patrick, Kelly (7 January 2006). "The drinks are on us at the homeless shelter: Served every 90 minutes: Managed alcohol program reduces drinking". National Post.
14. "DESC". 3 March 2016. Archived from the original on 3 March 2016. Retrieved 2 February 2021.
15. "SAPRP Project: Housing First: Evaluation of Harm Reduction Housing for Chronic Public Inebriates". SAPRP. April 2009. Archived from the original on 29 July 2010.
16. Larimer ME, Malone DK, Garner MD, et al. (April 2009). "Health care and public service use and costs before and after provision of housing for chronically homeless persons with severe alcohol problems". JAMA. 301 (13): 1349–1357. doi:10.1001/jama.2009.414. PMID 19336710.
17. Volpicelli, Joseph R.; Alterman, Arthur I.; Hayashida, Motoi; O'Brien, Charles P. (1 November 1992). "Naltrexone in the Treatment of Alcohol Dependence". Archives of General Psychiatry. 49 (11): 876–880. doi:10.1001/archpsyc.1992.01820110040006. PMID 1345133.
18. Uchtenhagen, Ambros (February 2002). "Background". Heroin Assisted Treatment for Opiate Addicts – The Swiss Experience. Archived from the original on 20 January 2010. Retrieved 15 March 2020.
19. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D (July 2007). "Heroin-assisted treatment for opioid dependence: randomised controlled trial". The British Journal of Psychiatry. 191: 55–62. doi:10.1192/bjp.bp.106.026112. PMID 17602126.
20. Uchtenhagen, Ambros (February 2002). "Epidemiology". Heroin Assisted Treatment for Opiate Addicts – The Swiss Experience. Archived from the original on 20 January 2010. Retrieved 15 March 2020.
21. Urs Geiser (30 November 2008). "Swiss to agree heroin scheme but say no to dope". Swissinfo.ch. Swiss Broadcasting Corporation. Archived from the original on 7 April 2014. Retrieved 21 May 2013.
22. van den Brink, Wim; Hendriks, Vincent M.; Blanken, Peter; Huijsman, Ineke A.; van Ree, Jan M. (2002). Medical Co-Prescription of Heroin: Two Randomized Controlled Trials. Central Committee on the Treatment of Heroin Addicts (CCBH). ISBN 9080693227. NCJ 195635. Archived from the original on 17 May 2006. Retrieved 21 March 2024.
23. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D (July 2007). "Heroin-assisted treatment for opioid dependence: randomised controlled trial". Br J Psychiatry. 191: 55–62. doi:10.1192/bjp.bp.106.026112. PMID 17602126.
24. "Heroin (diamorphine) supported treatment in Germany: Results and problems of implementation" (PDF). Commissioner on Narcotic Drugs. German Federal Ministry of Health. 2 May 2010. Retrieved 21 March 2024.
25. http://relaunch.bundestag.de/bundestag/ausschuesse/a14/anhoerungen/113/stllg/ZIS.pdf. Retrieved 9 September 2009. {{cite web}}: Missing or empty |title= (help)^{[dead link‍]}
26. Smith, Phillip (5 June 2009). "Europe: German Parliament Approves Heroin Maintenance". StoptheDrugWar.org. Archived from the original on 25 September 2009. Retrieved 11 August 2016.
27. van der Gouwe, Daan; Strada, Lisa; Diender, Bob; van Gelder, Nadine; de Gee, Anouk (2022). "Harm reduction services in the Netherlands: recent developments and future challenges" (PDF). Netherlands Institute of Mental Health and Addiction. Trimbos-instituut: 10. Archived (PDF) from the original on 14 January 2024. Retrieved 21 December 2023.
28. Rachel Lart. "British Medical Perception from Rolleston to Brain, Changing Images of the Addict and Addiction". Archived from the original on 10 June 2011.
29. Stimson, Gerry V; Metrebian, Nicky (12 September 2003). "Prescribing Heroin: what is the evidence?". Joseph Rowntree Foundation. Archived from the original on 9 February 2006.
30. "Nyheter – Norges forskningsråd". 29 March 2012. Archived from the original on 29 March 2012.
31. "Treatable or Just Hard to Treat?". Archived from the original on 8 August 2010. Retrieved 8 January 2011. 2009
32. "Arguments for Prohibition" (PDF). p. 3. Archived from the original (PDF) on 6 July 2011. Retrieved 20 April 2010.
33. "World Drug Report 2000". Archived from the original on 17 April 2010. Retrieved 4 May 2010. 2001 pp. 162–65 (see aggregated average for each OECD country in Harm Reduction Discussion page).
34. "Untreatable or Just Hard to Treat?". Archived from the original on 28 March 2010. Retrieved 20 April 2010.
35. Lintzeris, Nicholas (2009). "Prescription of heroin for the management of heroin dependence: current status". CNS Drugs. 23 (6): 463–476. doi:10.2165/00023210-200923060-00002. PMID 19480466. S2CID 11018732.
36. "Get Started". Open Society Foundations. 2013. Archived from the original on 14 March 2014. Retrieved 17 March 2014.
37. "Treatment of opioid dependence". World Health Organization. WHO. 2014. Archived from the original on 14 March 2014. Retrieved 17 March 2014.
38. "Drug use prevention, treatment and care". United Nations Office on Drugs and Crime. UNODC. 2014. Archived from the original on 10 September 2020. Retrieved 17 March 2014.
39. Paul Dietze; Simon Lenton (December 2010). "The case for the wider distribution of naloxone in Australia" (PDF). Alcohol, Tobacco & Other Drug Association ACT. ATODA. Archived from the original (PDF) on 11 April 2013. Retrieved 30 March 2013.
40. "Tools for Starting a Naloxone Program". Open Society Foundations. 2013. Archived from the original on 17 March 2014. Retrieved 17 March 2014.
41. "Take home naloxone to reduce fatalities: scaling up a participatory intervention across Europe". European Monitoring Centre for Drugs and Drug Addiction. Lisbon. 14 October 2014.
42. Mueller, Shane R.; Walley, Alexander Y.; Calcaterra, Susan L.; Glanz, Jason M.; Binswanger, Ingrid A. (3 April 2015). "A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice". Substance Abuse. 36 (2): 240–253. doi:10.1080/08897077.2015.1010032. PMC 4470731. PMID 25774771.
43. McDonald, Rebecca; Strang, John (30 March 2016). "Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria". Addiction. 111 (7): 1177–1187. doi:10.1111/add.13326. PMC 5071734. PMID 27028542.
44. Miller, Nicole M.; Waterhouse-Bradley, Bethany; Campbell, Claire; Shorter, Gillian W. (23 February 2022). "How do naloxone-based interventions work to reduce overdose deaths: a realist review". Harm Reduction Journal. 19 (1): 18. doi:10.1186/s12954-022-00599-4. PMC 8867850. PMID 35197057.
45. Noble, Florence; Marie, Nicolas (18 January 2019). "Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine". Frontiers in Psychiatry. 9: 742. doi:10.3389/fpsyt.2018.00742. PMC 6345716. PMID 30713510.
46. Mattick, Richard P.; et al. "National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): Report of Results and Recommendation" (PDF). Department of Health and Aged Care. Australian Government. Archived from the original (PDF) on 9 March 2011.
47. Soyka, Michael; Franke, Andreas G (19 September 2021). "Recent advances in the treatment of opioid use disorders – focus on long-acting buprenorphine formulations". World Journal of Psychiatry. 11 (9): 543–552. doi:10.5498/wjp.v11.i9.543. PMC 8474991. PMID 34631459.
48. "Opioid Agonist Treatment (OAT): The Gold Standard for Opioid Use Disorder Treatment". Drug Policy Alliance. Archived from the original on 8 June 2022. Retrieved 28 June 2022.
49. "Opioid vending machine opens in Vancouver". The Guardian. 17 February 2020. Archived from the original on 10 January 2022. Retrieved 10 January 2022.
50. Islam, M. Mofizal; Topp, Libby; Day, Carolyn A.; Dawson, Angela; Conigrave, Katherine M. (2012). "The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: A narrative synthesis of literature". International Journal of Drug Policy. 23 (2): 94–102. doi:10.1016/j.drugpo.2011.08.005. PMID 21996165.
51. Islam, M. Mofizal; Topp, Libby; Day, Carolyn A.; Dawson, Angela; Conigrave, Katherine M. (2012). "Primary healthcare outlets that target injecting drug users: Opportunity to make services accessible and acceptable to the target group". International Journal of Drug Policy. 23 (2): 109–10. doi:10.1016/j.drugpo.2011.11.001. PMID 22280917.
52. Islam, M. Mofizal; Reid, Sharon E.; White, Ann; Grummett, Sara; Conigrave, Katherine M.; Haber, Paul S. (2012). "Opportunistic and continuing health care for injecting drug users from a nurse-run needle syringe program-based primary health-care clinic". Drug Alcohol Rev. 31 (1): 114–115. doi:10.1111/j.1465-3362.2011.00390.x. PMID 22145983.
53. Islam, M. Mofizal (2010). "Needle Syringe Program-Based Primary Health Care Centers: Advantages and Disadvantages". Journal of Primary Care & Community Health. 1 (2): 100–03. doi:10.1177/2150131910369684. PMID 23804370. S2CID 8663924.
54. Harris, Hobart W.; Young, D. M. (2002). "Care of injection drug users with soft tissue infections in San Francisco, California". Arch Surg. 137 (11): 1217–1222. doi:10.1001/archsurg.137.11.1217. PMID 12413304.
55. Pollack, Harold A.; Khoshnood, Kaveh; Blankenship, Kim M.; Altice, Frederick L. (2002). "The impact of needle exchange-based health services on emergency department use". Journal of General Internal Medicine. 17 (5): 341–348. doi:10.1007/s11606-002-0037-2. PMC 1495047. PMID 12047730.
56. Wayne Hall; Benedikt Fischer. "Chapter 8 : Harm reduction policies for cannabis" (PDF). Harm reduction: evidence, impacts, and challenges. Archived from the original (PDF) on 14 January 2011. Retrieved 11 August 2016.
57. "Fact Sheet: Impact of Drug Convictions on Individual Lives" (PDF). Kcba.org. Archived from the original (PDF) on 2 January 2011. Retrieved 11 August 2016.
58. Hall W, Fischer B. "Chapter 8: Harm reduction policies for cannabis" (PDF). Archived from the original (PDF) on 9 August 2021. Retrieved 23 June 2010.
59. "Should Latin America End the War on Drugs?". The New York Times. 13 January 2014. Archived from the original on 8 April 2023. Retrieved 4 March 2017.
60. "Amsterdam Will Ban Tourists from Pot Coffee Shops". Atlantic Wire. 27 May 2011. Archived from the original on 26 December 2018. Retrieved 23 June 2011.
61. "Drug policy profiles – Portugal". Europa (web portal). Archived from the original on 4 February 2024. Retrieved 14 July 2023.
62. "Zendo Project: Psychedelic Harm Reduction". Multidisciplinary Association for Psychedelic Studies – MAPS. Archived from the original on 5 January 2022. Retrieved 5 January 2022.
63. "TREATMENT OF STIMULANT USE DISORDERS: CURRENT PRACTICES AND PROMISING PERSPECTIVES" (PDF).
64. Mangia, Jim (22 January 2020). "Opinion | Gay Men Are Dying From a Crisis We're Not Talking About". The New York Times. ISSN 0362-4331. Archived from the original on 10 February 2023. Retrieved 10 February 2023.
65. Urell, Aaryn (9 December 2019). "Crack vs. Heroine Project: Racial Double Standard in Drug Laws Persists Today". Equal Justice Initiative. Archived from the original on 10 February 2023. Retrieved 10 February 2023.
66. Taxy, S; Samuels, J; Adams, W (October 2015). Drug offenders in federal prison: Estimates of characteristics based on linked data (PDF) (Report). Washington, DC: US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics.
67. Centers for Disease Control Prevention (CDC) (July 2008). "Nonpharmaceutical fentanyl-related deaths – multiple states, April 2005 – March 2007" (PDF). MMWR Morb Mortal Wkly Rep. 57 (29): 793–796. PMID 18650786. Archived from the original (PDF) on 2 December 2022. Retrieved 2 December 2022.
68. Farsalinos, Konstantinos; LeHouezec, Jacques (September 2015). "Regulation in the face of uncertainty: the evidence on electronic nicotine delivery systems (e-cigarettes)". Risk Management and Healthcare Policy. 8: 157–167. doi:10.2147/RMHP.S62116. PMC 4598199. PMID 26457058.
69. Drummond, M. Bradley; Upson, Dona (February 2014). "Electronic Cigarettes. Potential Harms and Benefits". Annals of the American Thoracic Society. 11 (2): 236–242. doi:10.1513/AnnalsATS.201311-391FR. PMC 5469426. PMID 24575993.
70. Cahn, Zachary; Siegel, Michael (February 2011). "Electronic cigarettes as a harm reduction strategy for tobacco control: A step forward or a repeat of past mistakes?". Journal of Public Health Policy. 32 (1): 16–31. doi:10.1057/jphp.2010.41. PMID 21150942.
71. McNeil, Donald G. (12 July 2010). "Desperate Addicts Inject Others' Blood". The New York Times. Gale A231383957. Archived from the original on 28 May 2023. Retrieved 8 July 2022.
72. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D (May 2010). "Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews". Addiction. 105 (5): 844–859. doi:10.1111/j.1360-0443.2009.02888.x. PMID 20219055.
73. Hilton, B. Ann; Thompson, Ray; Moore-Dempsey, Laura; Janzen, Randy G. (28 February 2001). "Harm reduction theories and strategies for control of human immunodeficiency virus: a review of the literature". Journal of Advanced Nursing. 33 (3): 357–370. doi:10.1046/j.1365-2648.2001.01672.x. PMID 11251723.
74. Lucie Van Den Berg (20 May 2013). "Syringe machine push for addicts in Melbourne's heroin hot spots". The Australian. Archived from the original on 13 March 2020. Retrieved 20 May 2013.
75. Bridie Byrne (28 May 2013). "Drug experts propose needle vending machines for Footscray". Herald Sun. Retrieved 12 February 2023.
76. Charlie Cooper (9 April 2014). "NICE: Needle exchanges should supply safe equipment to under-18 steroid users". The Independent. London. Archived from the original on 9 May 2022. Retrieved 9 April 2014.
77. Dolan, Kate; Kimber, Jo; Fry, Craig; Fitzgerald, John; McDonald, David; Trautmann, Franz (September 2000). "Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia". Drug and Alcohol Review. 19 (3): 337–346. doi:10.1080/713659379.
78. Hedrich D, et al. "Chapter 11: Drug consumption facilities in Europe and beyond" (PDF). Archived from the original (PDF) on 25 February 2021. Retrieved 23 June 2010.
79. Pollard R (8 July 2006). "1700 overdoses that didn't end in death". The Sydney Morning Herald. Archived from the original on 19 February 2011. Retrieved 9 June 2010.
80. "Timeline: Insite". Canadian Broadcasting Corporation. 13 March 2009. Archived from the original on 7 December 2009. Retrieved 9 June 2010.
81. "Sydney gets first supervised heroin injecting room". The Independent. London: Independent Print Limited. 5 April 2001. Retrieved 21 September 2010.^{[dead link‍]}
82. "Drug experts support injecting centre". The Sydney Morning Herald. 15 October 2010. Archived from the original on 20 August 2012. Retrieved 21 October 2010.
83. Simmons, Amy (16 September 2010). "Injecting centre approval fails to quell controversy". ABC News. Australian Broadcasting Corporation. Archived from the original on 25 June 2011. Retrieved 21 October 2010.
84. Government of Canada, Health Canada (22 May 2018). "Interactive map: Canada's response to the opioid crisis". health.canada.ca. Archived from the original on 11 January 2024. Retrieved 9 June 2023.
85. Plante, Alexandra (5 October 2022). "Understanding Morals Is Key to Accepting Safe Injection Sites". Scientific American. Archived from the original on 28 September 2023. Retrieved 28 September 2023.
86. Rehm J, et al. "Chapter 4: Perspectives on harm reduction – what experts have to say" (PDF). Archived from the original (PDF) on 9 August 2021. Retrieved 23 June 2010.
87. "Drug Free Australia Detailed Evidence on Sydney MSIC" (PDF). Archived from the original (PDF) on 15 February 2011. Retrieved 9 January 2010.
88. "The Vancouver Drug Injection site must be shut down". Real Women of Canada. Archived from the original on 3 November 2002. Retrieved 9 January 2010.
89. EMCDDA 2010, p. 308
90. "Sydney Medically Supervised Injecting Centre Evaluation Report No. 4" (PDF). p. 35. Archived from the original (PDF) on 29 October 2009. Retrieved 9 January 2010.
91. "Final Report of the Vancouver Insite Expert Advisory Committee". 3 April 2008. Archived from the original on 14 May 2017. Retrieved 19 April 2010. 2008
92. "Final Report of the Vancouver Insite Expert Advisory Committee". 3 April 2008. Archived from the original on 14 May 2017. Retrieved 19 April 2010.
93. Clement, T. "Canadian Parliament 39:2 Hansard – 103 (2008-06-02)". Archived from the original on 13 October 2012. Retrieved 31 May 2010.
94. "The Case for Closure: Detailed Evidence" (PDF). Drug Free Australia. pp. 26–27. Archived from the original (PDF) on 15 February 2011. Retrieved 9 January 2010.
95. "The Case for Closure: Detailed Evidence" (PDF). Drug Free Australia. pp. 31–34. Archived from the original (PDF) on 15 February 2011. Retrieved 9 January 2010.
96. "Final Report of the Evaluation of the Sydney Medically Supervised Injecting Centre" (PDF). p. 147. Archived from the original (PDF) on 29 October 2009. Retrieved 9 January 2010.
97. Canada, Health (22 July 2021). "Safer supply: Prescribed medications as a safer alternative to toxic illegal drugs". canada.ca. Archived from the original on 19 January 2024. Retrieved 9 June 2023.
98. Joseph, Andrew (21 September 2022). "'This program's really saved us': As Canada offers safer opioids to curb overdoses, will U.S. follow?". Archived from the original on 9 June 2023. Retrieved 9 June 2023.
99. Johnson, BT; Scott-Sheldon, LA; Huedo-Medina, TB; Carey, MP (January 2011). "Interventions to reduce sexual risk for human immunodeficiency virus in adolescents: a meta-analysis of trials, 1985–2008". Archives of Pediatrics & Adolescent Medicine. 165 (1): 77–84. doi:10.1001/archpediatrics.2010.251. PMC 4361805. PMID 21199984.
100. Oringanje, Chioma; Meremikwu, Martin M; Eko, Hokehe; Esu, Ekpereonne; Meremikwu, Anne; Ehiri, John E (3 February 2016). "Interventions for preventing unintended pregnancies among adolescents". Cochrane Database of Systematic Reviews. 2016 (2): CD005215. doi:10.1002/14651858.CD005215.pub3. PMC 8730506. PMID 26839116.
101. Underhill, Kristen; Operario, Don; Montgomery, Paul (17 October 2007). "Abstinence-only programs for HIV infection prevention in high-income countries". Cochrane Database of Systematic Reviews (4): CD005421. doi:10.1002/14651858.CD005421.pub2. PMID 17943855.
102. AlwaysUnite (11 April 2015). "Paar honderd prostituees protesteren tegen sluiting raambordelen". National Daily. Archived from the original on 31 March 2016. Retrieved 10 April 2015.
103. Fuchs, Erin (13 November 2013). "7 Reasons Why America Should Legalize Prostitution". Business Insider. Archived from the original on 2 December 2021. Retrieved 7 March 2022.
104. Phasuk, Sunai (2004). Thailand, not enough graves: the war on drugs, HIV/AIDS, and violations of human rights (Report). Human Rights Watch. OCLC 56024188. Archived from the original on 4 December 2023. Retrieved 8 July 2022.
105. Rekart ML (December 2005). "Sex-work harm reduction". Lancet. 366 (9503): 2123–2134. doi:10.1016/S0140-6736(05)67732-X. PMID 16360791. S2CID 11448309.
106. O’Hare, Pat (March 2007). "Merseyside, the first harm reduction conferences, and the early history of harm reduction". International Journal of Drug Policy. 18 (2): 141–144. doi:10.1016/j.drugpo.2007.01.003. PMID 17689357.
107. Indian Social Institute (2011). HIV/AIDS – 2011 (Report). Human Rights Documents Online. doi:10.1163/2210-7975_hrd-0510-0080.
108. "The International Task Force Meeting Statement on So-Called 'Harm Reduction' Policies" (PDF). Itfsdp.org. Archived from the original (PDF) on 6 August 2016. Retrieved 11 August 2016.
109. "WFAD Declaration | World Federation Against Drugs". Wfad.se. Archived from the original on 23 July 2016. Retrieved 11 August 2016.
110. "Drug Prevention Network Canada – Harm Reduction". 24 April 2010. Archived from the original on 24 April 2010. Retrieved 11 August 2016.
111. "Declaration of World Forum Against Drugs" (PDF). Archived from the original (PDF) on 2 October 2008. Retrieved 13 September 2008.
112. "Condoms 'not the answer to AIDS': Pope". World News Australia. SBS. 17 March 2009. Archived from the original on 15 June 2013. Retrieved 23 June 2010.
113. Kamerow D (2009). "The papal position on condoms and HIV". BMJ. 338: b1217. doi:10.1136/bmj.b1217. PMID 19321547. S2CID 30450691.
114. Roehr B (2009). "Pope claims that condoms exacerbate HIV and AIDS problem". BMJ. 338: b1206. doi:10.1136/bmj.b1206. PMID 19321545. S2CID 27621688.

Further reading

• Hassan, Shira; Lewis, Deana G. (2022). Saving our own lives: a liberatory practice of harm reduction. Chicago, IL: Haymarket Books. ISBN 978-1-64259-841-4. OCLC 1315537122.

External links

• Media related to Harm reduction at Wikimedia Commons
• Drugs Policy and Harm Reduction Archived 10 May 2012 at the Wayback Machine – Research on the circulation of ideas around harm reduction and urban drug policies by Eugene McCann and Cristina Temenos (Simon Fraser University).
• Harm reduction: evidence, impacts and challenges. Lisbon: EMCDDA. April 2010. ISBN 978-92-9168-419-9.
• TNI on Harm Reduction
• Tobacco Harm Reduction Archived 29 December 2021 at the Wayback Machine